Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in ME/CFS
NCT04622293Phase 4Completed
- Sponsor
- Rochester Center for Behavioral Medicine
- Start
- Apr 2021
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of solriamfetol in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), sponsored by Rochester Center for Behavioral Medicine. Started Apr 2021; status: completed.
02
Drugs
solriamfetol
03
Conditions
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT04622293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622293.